DNA synthesis cost collapse (2007-2015)
Next-generation sequencing and silicon-based DNA synthesis drove the cost of reading and writing DNA down by orders of magnitude. Companies like Twist Bioscience built business models around cheap, high-volume synthetic DNA.
Whole-genome sequencing became affordable for research labs.
Low-cost synthesis made large-scale protein and antibody production feasible, enabling the AI-driven pipeline now emerging.
The Twist-PROTEINA deal depends on the cost curve that made it economical to physically validate thousands of AI-designed antibody candidates.
